Literature DB >> 23744500

No need for broad-spectrum empirical antibiotic coverage after surgical drainage of orthopaedic implant infections.

Maximilian Schindler1, Axel Gamulin, Wilson Belaieff, Maruschka Francescato, Alexis Bonvin, Véronique Graf, Pierre Hoffmeyer, Blaise Wyssa, Ilker Uçkay.   

Abstract

PURPOSE: Empirical broad-spectrum antibiotic treatment for orthopaedic implant infections after surgical lavage is common practice while awaiting microbiological results, but lacks evidence.
METHODS: This was a single-centre cohort study from 1996 to 2010 with a follow-up of two years.
RESULTS: We retrieved 342 implant infections and followed them up for a median of 3.5 years (61 recurred, 18%). Infected implants were arthroplasties (n = 186), different plates, nails or other osteosyntheses. The main pathogens were S. aureus (163, 49 methicillin-resistant) and coagulase-negative staphylococci (60, 45 methicillin-resistant). Median duration of empirical antibiotic coverage after surgical drainage was three days before switching to targeted therapy. Vancomycin was the most frequent initial empirical agent (147), followed by intravenous co-amoxiclav (44). Most empirical antibiotic regimens (269, 79%) proved sensitive to the causative pathogen, but were too broad in 111 episodes (32%). Cephalosporins and penicillins were used only in 44 and ten cases, respectively, although they would have covered 59% of causative pathogens identified later. Multivariate Cox regression analysis showed that neither susceptible antibiotic coverage (compared to non-susceptible; hazard ratio 0.7, 95% confidence interval 0.4-1.2) nor broad-spectrum use (hazard ratio 1.1, 0.8-1.5) changed remission rates.
CONCLUSIONS: Provided that surgical drainage is performed, broad-spectrum antibiotic coverage does not enhance remission of orthopaedic implant infections during the first three days. If empirical agents are prescribed from the first day of infection, narrow-spectrum penicillins or cephalosporins can be considered to avoid unnecessary broad-spectrum antibiotic use.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744500      PMCID: PMC3779563          DOI: 10.1007/s00264-013-1924-3

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  16 in total

1.  Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance.

Authors:  S Harbarth; M H Samore; D Lichtenberg; Y Carmeli
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

Review 2.  Preventing surgical site infections.

Authors:  Ilker Uçkay; Stephan Harbarth; Robin Peter; Daniel Lew; Pierre Hoffmeyer; Didier Pittet
Journal:  Expert Rev Anti Infect Ther       Date:  2010-06       Impact factor: 5.091

3.  Empirical antibiotic therapy in prosthetic joint infections.

Authors:  Ricardo Sousa; Alexandre Pereira; Marta Massada; Manuel Vieira da Silva; Rui Lemos; José Costa e Castro
Journal:  Acta Orthop Belg       Date:  2010-04       Impact factor: 0.500

Review 4.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

5.  Relaxing the rule of ten events per variable in logistic and Cox regression.

Authors:  Eric Vittinghoff; Charles E McCulloch
Journal:  Am J Epidemiol       Date:  2006-12-20       Impact factor: 4.897

6.  Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2013-01       Impact factor: 9.079

7.  The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens.

Authors:  S H Sheehy; B A Atkins; P Bejon; I Byren; D Wyllie; N A Athanasou; A R Berendt; M A McNally
Journal:  J Infect       Date:  2010-03-15       Impact factor: 6.072

Review 8.  A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.

Authors:  G Cranny; R Elliott; H Weatherly; D Chambers; N Hawkins; L Myers; M Sculpher; A Eastwood
Journal:  Health Technol Assess       Date:  2008-01       Impact factor: 4.014

9.  Culture-negative prosthetic joint infection.

Authors:  Elie F Berbari; Camelia Marculescu; Irene Sia; Brian D Lahr; Arlen D Hanssen; James M Steckelberg; Rachel Gullerud; Douglas R Osmon
Journal:  Clin Infect Dis       Date:  2007-09-26       Impact factor: 9.079

10.  Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention.

Authors:  E Moran; S Masters; A R Berendt; P McLardy-Smith; I Byren; B L Atkins
Journal:  J Infect       Date:  2007-03-06       Impact factor: 6.072

View more
  3 in total

1.  Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018).

Authors:  María Galán-Olleros; Javier Marco; David Oteo; Rafael Cristóbal-Bilbao; Elena Manrique; Roberto García-Maroto; Fernando Marco; Juan Luis Cebrián-Parra
Journal:  Ann Surg Oncol       Date:  2020-07-13       Impact factor: 5.344

2.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

3.  How good are clinicians in predicting the presence of Pseudomonas spp. in diabetic foot infections? A prospective clinical evaluation.

Authors:  Ilker Uçkay; Dominique Holy; Madlaina Schöni; Felix W A Waibel; Tudor Trache; Jan Burkhard; Thomas Böni; Benjamin A Lipsky; Martin C Berli
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.